229 related articles for article (PubMed ID: 11391724)
1. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma.
Shvidel L; Klepfish A; Berrebi A
Am J Hematol; 2001 Jul; 67(3):213-4. PubMed ID: 11391724
[No Abstract] [Full Text] [Related]
2. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
4. Splenectomy for treatment of immune thrombocytopenic purpura.
Malcovati L; Della Porta MG
Haematologica; 2005 Jan; 90(1):4. PubMed ID: 15644305
[No Abstract] [Full Text] [Related]
5. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
6. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Cooper N; Evangelista ML; Amadori S; Stasi R
Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
[TBL] [Abstract][Full Text] [Related]
7. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
8. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).
Narang M; Penner JA; Williams D
Am J Hematol; 2003 Dec; 74(4):263-7. PubMed ID: 14635207
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
10. Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab.
El-Shanawany TM; Williams PE; Jolles S
J Clin Pathol; 2007 Jun; 60(6):715-6. PubMed ID: 17483248
[No Abstract] [Full Text] [Related]
11. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
14. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
Moschovi M; Trimis G; Pergantou H; Platokouki H; Vrachnou E; Tzortzatou-Stathopoulou F
J Paediatr Child Health; 2005 Jul; 41(7):384-6. PubMed ID: 16014149
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
Delgado J; Bustos JG; Jimenez-Yuste V; Hernandez-Navarro F
Haematologica; 2002 Feb; 87(2):215-6. PubMed ID: 11836172
[TBL] [Abstract][Full Text] [Related]
16. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
Riksen NP; Keuning JJ; Vreugdenhil G
Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
19. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders.
Liebman HA
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S33-6. PubMed ID: 19245932
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
